Viral clearance Market By Method (Viral Removal, Viral Inactivation), By Application (Recombinant Proteins, Blood and Blood Products, Cellular and Gene Therapy Products, Vaccine, Other Applications), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global viral clearance market was valued at $425.93 million in 2021, and is projected to reach $977.84 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.
Viral clearance is the removal of viral contamination using specialized membranes (mostly proteins) or chromatography. These protein solutions undergo viral clearance to inactivate or remove viral materials to ensure that therapeutic drugs derived from certain sources are fully rid of any viral contamination.
Viral clearance is a critical step in the manufacturing process that helps assure the safety of biologics such as biosimilars, antibodies, stem cell products, biopharmaceuticals, and others. Pharmaceutical and other product manufacturers need to be confirmed of its purification and manufacturing processes' capacity to inactivate or eliminate viruses or Transmissible spongiform encephalopathies(TSE) agents, as well as assure product safety.
The key factors that drive the growth of the market are rise in investments in the biotechnology and the pharmaceutical companies. There has been a rise in drug launches, increase in R&D investments, and rise in the possibility of cell culture contamination, recent advancements in nano-filtration technology, large economic burden and incidence of chronic diseases which is projected to provide huge opportunities for the growth of the viral clearance market. Along with this, rise in pharmaceutical outsourcing and increase in emerging markets are creating opportunities for the growth of the viral clearance market.
However, ever increasing cost and time-intensive drug development process are creating hurdles in the viral clearance market. In addition, increased degree of consolidation is also obstructing the growth of the market.
The viral clearance market is segmented on the basis of method, application, end user, and region. By method, it is categorized into viral removal, and viral inactivation. Viral removal is further divided into chromatography, nanofiltration, and precipitation. Viral inactivation is further categorized into low pH, solvent detergent method, heat pasteurization, and other viral inactivation methods. Depending on application, it is classified into recombinant proteins, blood and blood products, cellular and gene therapy products, vaccines, and other applications. By end user, it is categorized into pharmaceutical & biotechnology companies, contract research organizations, academic research institutes, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
North America accounted for the largest market share in the viral clearance market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in demand for biopharmaceutical and upsurge in demand for advanced technologies in the purification of recombinant proteins produced by animal cell cultures to create high-value products of modern biotechnology.
The report provides a comprehensive analysis of the key players that operate in the global viral clearance market. The key companies profiled in the report include Allure Medical Group, Charles River Laboratories International, Inc., Clean Cells, Creative Biogene, Eurofins Scientific SE, Maravai Lifesciences Holding, Inc., Merck KGaA, Sartorius Stedium Biotech, Syngene International Limited, and Wuxi Biologics Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the viral clearance market analysis from 2021 to 2031 to identify the prevailing viral clearance market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the viral clearance market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global viral clearance market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Method
Viral Removal
Type
Chromatography
Nanofiltration
Precipitation
Viral Inactivation
Type
Low pH
Solvent Detergent Method
Heat Pasteurization
Other Viral Inactivation Methods
By Application
Recombinant Proteins
Blood and Blood Products
Cellular and Gene Therapy Products
Vaccine
Other Applications
By End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic Research Institutes
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Italy
Spain
Germany
France
UK
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
ALLURE MEDICAL GROUP
Charles River Laboratories International, Inc.
CLEAN CELLS
CREATIVE BIOGENE
EUROFINS SCIENTIFIC SE
MARAVAI LIFESCIENCES HOLDINGS, INC.
MERCK KGAA
SARTORIUS STEDIM BIOTECH
SYNGENE INTERNATIONAL LIMITED
WUXI BIOLOGICS INC.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: VIRAL CLEARANCE MARKET, BY METHOD
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Viral Removal
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Viral Removal Viral clearance Market by Type
- 4.3 Viral Inactivation
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Viral Inactivation Viral clearance Market by Type
- CHAPTER 5: VIRAL CLEARANCE MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Recombinant Proteins
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Blood and Blood Products
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Cellular and Gene Therapy Products
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Vaccine
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Other Applications
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- CHAPTER 6: VIRAL CLEARANCE MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Pharmaceutical and Biotechnology Companies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Contract Research Organizations
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Academic Research Institutes
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- CHAPTER 7: VIRAL CLEARANCE MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Method
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Method
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Method
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Method
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Method
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Method
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Method
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Method
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Method
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Method
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Method
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Method
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Method
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Method
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Method
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Method
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Method
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Method
- 7.4.5.6.2 Market size and forecast, by Application
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Method
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Method
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 South Africa
- 7.5.5.2.1 Market size and forecast, by Method
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 Saudi Arabia
- 7.5.5.3.1 Market size and forecast, by Method
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Method
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 ALLURE MEDICAL GROUP
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Charles River Laboratories International, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 CLEAN CELLS
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 CREATIVE BIOGENE
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 EUROFINS SCIENTIFIC SE
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 MARAVAI LIFESCIENCES HOLDINGS, INC.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 MERCK KGAA
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 SARTORIUS STEDIM BIOTECH
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 SYNGENE INTERNATIONAL LIMITED
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 WUXI BIOLOGICS INC.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 2. VIRAL CLEARANCE MARKET SIZE, FOR VIRAL REMOVAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. VIRAL CLEARANCE MARKET FOR VIRAL REMOVAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. GLOBAL VIRAL REMOVAL VIRAL CLEARANCE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 5. VIRAL CLEARANCE MARKET SIZE, FOR VIRAL INACTIVATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 6. VIRAL CLEARANCE MARKET FOR VIRAL INACTIVATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 7. GLOBAL VIRAL INACTIVATION VIRAL CLEARANCE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 8. GLOBAL VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 9. VIRAL CLEARANCE MARKET SIZE, FOR RECOMBINANT PROTEINS, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. VIRAL CLEARANCE MARKET FOR RECOMBINANT PROTEINS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. VIRAL CLEARANCE MARKET SIZE, FOR BLOOD AND BLOOD PRODUCTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. VIRAL CLEARANCE MARKET FOR BLOOD AND BLOOD PRODUCTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. VIRAL CLEARANCE MARKET SIZE, FOR CELLULAR AND GENE THERAPY PRODUCTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. VIRAL CLEARANCE MARKET FOR CELLULAR AND GENE THERAPY PRODUCTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. VIRAL CLEARANCE MARKET SIZE, FOR VACCINE, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. VIRAL CLEARANCE MARKET FOR VACCINE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. VIRAL CLEARANCE MARKET SIZE, FOR OTHER APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. VIRAL CLEARANCE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. GLOBAL VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 20. VIRAL CLEARANCE MARKET SIZE, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. VIRAL CLEARANCE MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. VIRAL CLEARANCE MARKET SIZE, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. VIRAL CLEARANCE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. VIRAL CLEARANCE MARKET SIZE, FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. VIRAL CLEARANCE MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. VIRAL CLEARANCE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. VIRAL CLEARANCE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. VIRAL CLEARANCE MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA VIRAL CLEARANCE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 33. U.S. VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 34. U.S. VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 35. U.S. VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 36. CANADA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 37. CANADA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 38. CANADA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 39. MEXICO VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 40. MEXICO VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 41. MEXICO VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 42. EUROPE VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 43. EUROPE VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 44. EUROPE VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 45. EUROPE VIRAL CLEARANCE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 46. GERMANY VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 47. GERMANY VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 48. GERMANY VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 49. FRANCE VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 50. FRANCE VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 51. FRANCE VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 52. UK VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 53. UK VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 54. UK VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 55. ITALY VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 56. ITALY VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 57. ITALY VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 58. SPAIN VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 59. SPAIN VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 60. SPAIN VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 68. CHINA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 69. CHINA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 70. CHINA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 71. JAPAN VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 72. JAPAN VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 73. JAPAN VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 74. INDIA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 75. INDIA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 76. INDIA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 77. AUSTRALIA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 80. SOUTH KOREA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 81. SOUTH KOREA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 83. REST OF ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 84. REST OF ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 86. LAMEA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 87. LAMEA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 88. LAMEA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 89. LAMEA VIRAL CLEARANCE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 90. BRAZIL VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 91. BRAZIL VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 93. SOUTH AFRICA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 94. SOUTH AFRICA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 95. SOUTH AFRICA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 98. SAUDI ARABIA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 99. REST OF LAMEA VIRAL CLEARANCE MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 100. REST OF LAMEA VIRAL CLEARANCE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA VIRAL CLEARANCE MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 102.ALLURE MEDICAL GROUP: COMPANY SNAPSHOT
- TABLE 103.ALLURE MEDICAL GROUP: OPERATING SEGMENTS
- TABLE 104.ALLURE MEDICAL GROUP: PRODUCT PORTFOLIO
- TABLE 105.ALLURE MEDICAL GROUP: NET SALES,
- TABLE 106.ALLURE MEDICAL GROUP: KEY STRATERGIES
- TABLE 107.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
- TABLE 108.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
- TABLE 109.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
- TABLE 110.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: NET SALES,
- TABLE 111.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATERGIES
- TABLE 112.CLEAN CELLS: COMPANY SNAPSHOT
- TABLE 113.CLEAN CELLS: OPERATING SEGMENTS
- TABLE 114.CLEAN CELLS: PRODUCT PORTFOLIO
- TABLE 115.CLEAN CELLS: NET SALES,
- TABLE 116.CLEAN CELLS: KEY STRATERGIES
- TABLE 117.CREATIVE BIOGENE: COMPANY SNAPSHOT
- TABLE 118.CREATIVE BIOGENE: OPERATING SEGMENTS
- TABLE 119.CREATIVE BIOGENE: PRODUCT PORTFOLIO
- TABLE 120.CREATIVE BIOGENE: NET SALES,
- TABLE 121.CREATIVE BIOGENE: KEY STRATERGIES
- TABLE 122.EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT
- TABLE 123.EUROFINS SCIENTIFIC SE: OPERATING SEGMENTS
- TABLE 124.EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO
- TABLE 125.EUROFINS SCIENTIFIC SE: NET SALES,
- TABLE 126.EUROFINS SCIENTIFIC SE: KEY STRATERGIES
- TABLE 127.MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY SNAPSHOT
- TABLE 128.MARAVAI LIFESCIENCES HOLDINGS, INC.: OPERATING SEGMENTS
- TABLE 129.MARAVAI LIFESCIENCES HOLDINGS, INC.: PRODUCT PORTFOLIO
- TABLE 130.MARAVAI LIFESCIENCES HOLDINGS, INC.: NET SALES,
- TABLE 131.MARAVAI LIFESCIENCES HOLDINGS, INC.: KEY STRATERGIES
- TABLE 132.MERCK KGAA: COMPANY SNAPSHOT
- TABLE 133.MERCK KGAA: OPERATING SEGMENTS
- TABLE 134.MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 135.MERCK KGAA: NET SALES,
- TABLE 136.MERCK KGAA: KEY STRATERGIES
- TABLE 137.SARTORIUS STEDIM BIOTECH: COMPANY SNAPSHOT
- TABLE 138.SARTORIUS STEDIM BIOTECH: OPERATING SEGMENTS
- TABLE 139.SARTORIUS STEDIM BIOTECH: PRODUCT PORTFOLIO
- TABLE 140.SARTORIUS STEDIM BIOTECH: NET SALES,
- TABLE 141.SARTORIUS STEDIM BIOTECH: KEY STRATERGIES
- TABLE 142.SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT
- TABLE 143.SYNGENE INTERNATIONAL LIMITED: OPERATING SEGMENTS
- TABLE 144.SYNGENE INTERNATIONAL LIMITED: PRODUCT PORTFOLIO
- TABLE 145.SYNGENE INTERNATIONAL LIMITED: NET SALES,
- TABLE 146.SYNGENE INTERNATIONAL LIMITED: KEY STRATERGIES
- TABLE 147.WUXI BIOLOGICS INC.: COMPANY SNAPSHOT
- TABLE 148.WUXI BIOLOGICS INC.: OPERATING SEGMENTS
- TABLE 149.WUXI BIOLOGICS INC.: PRODUCT PORTFOLIO
- TABLE 150.WUXI BIOLOGICS INC.: NET SALES,
- TABLE 151.WUXI BIOLOGICS INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.VIRAL CLEARANCE MARKET SEGMENTATION
- FIGURE 2.VIRAL CLEARANCE MARKET,2021-2031
- FIGURE 3.VIRAL CLEARANCE MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.VIRAL CLEARANCE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.VIRAL CLEARANCE MARKET,BY METHOD,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF VIRAL REMOVAL VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF VIRAL INACTIVATION VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 15.VIRAL CLEARANCE MARKET,BY APPLICATION,2021(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RECOMBINANT PROTEINS VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF BLOOD AND BLOOD PRODUCTS VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CELLULAR AND GENE THERAPY PRODUCTS VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF VACCINE VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 21.VIRAL CLEARANCE MARKET,BY END USER,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ACADEMIC RESEARCH INSTITUTES VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS VIRAL CLEARANCE MARKET,2021-2031(%)
- FIGURE 26.VIRAL CLEARANCE MARKET BY REGION,2021
- FIGURE 27.U.S. VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 28.CANADA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 29.MEXICO VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 30.GERMANY VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 31.FRANCE VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 32.UK VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 33.ITALY VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 34.SPAIN VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 35.REST OF EUROPE VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 36.CHINA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 37.JAPAN VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 39.AUSTRALIA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 40.SOUTH KOREA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 41.REST OF ASIA-PACIFIC VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 42.BRAZIL VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 43.SOUTH AFRICA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 44.SAUDI ARABIA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 45.REST OF LAMEA VIRAL CLEARANCE MARKET,2021-2031($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50.COMPETITIVE DASHBOARD
- FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 52.ALLURE MEDICAL GROUP.: NET SALES ,($MILLION)
- FIGURE 53.CHARLES RIVER LABORATORIES INTERNATIONAL, INC..: NET SALES ,($MILLION)
- FIGURE 54.CLEAN CELLS.: NET SALES ,($MILLION)
- FIGURE 55.CREATIVE BIOGENE.: NET SALES ,($MILLION)
- FIGURE 56.EUROFINS SCIENTIFIC SE.: NET SALES ,($MILLION)
- FIGURE 57.MARAVAI LIFESCIENCES HOLDINGS, INC..: NET SALES ,($MILLION)
- FIGURE 58.MERCK KGAA.: NET SALES ,($MILLION)
- FIGURE 59.SARTORIUS STEDIM BIOTECH.: NET SALES ,($MILLION)
- FIGURE 60.SYNGENE INTERNATIONAL LIMITED.: NET SALES ,($MILLION)
- FIGURE 61.WUXI BIOLOGICS INC..: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook